Comparison of quality of life in patients with chronic obstructive pulmonary disease vaccinated with 13-valent conjugate pneumococcal vaccine or 23-valent polysaccharide pneumococcal vaccine

Костинов, М. П.; Жестков, А. В.; Протасов, А. Д.; Костинова, Т. А.; Пахомов, Д. В.; Чебыкина, А. В.; Магаршак, О О

doi:10.18093/0869-0189-2015-25-2-163-166

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The resulting indicator was also relevant for calculating the probable number of PN cases that would have occurred without preventive vaccination after 2018 for 10 years (Table 4). Based on the aforementioned, the calculation was carried out according to the following formula [10]:…”

Section: Issn 2307-9266 E-issn 2413-2241mentioning

confidence: 99%

See 1 more Smart Citation

Pharmacoeconomic Evaluation of Anti-Pneumococcal Vaccination in Risk Groups for the Prevention of Community-Acquired Pneumonia Among Adults in the Astrakhan Region

Орлова

Дорфман

Орлов

et al. 2021

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

The aim. To evaluate the economic efficiency and the choice of the vaccination strategy in the respiratory pneumococcal infection risk groups among the adult population of the Astrakhan region.Materials and methods. The data for the period of 2015 - 2018 were analyzed on the number of registered diseases in the patients living in the service area of the medical organizations (Form No. 12, Federal State Statistics Service Orders No. 591, dated 27 November, 2015; No. 679, dated 22 November, 2019). The following working directives were studied: the base medical examination documentation submitted by medical institutions (Form No. 030/y “Dispensary Monitoring Checklist”; lists of the persons subjected to medical observation in the reporting year; Orders of the Ministry of Health of the Russian Federation: No. 1344, dated 12 December, 2012; No. 173n, dated 29 March, 2019). Statistical materials of the territorial fund for compulsory medical insurance of the Astrakhan region on the payment of medical care to 12,970 patients who had had pneumonia in 2015-2018, were analyzed. The financial support of vaccination based on the results of tenders for the procurement of pneumococcal vaccines organized by the regional Ministry of Health, was considered. The calculations were carried out in accordance with the guidelines of “Cost-effectiveness of vaccine prophylaxis” (Methodological guidelines 3.3.1878-04, dated 04.03.2004).Results. The prospective calculation of the vaccination cost showed that the benefits of vaccination with pneumococcal conjugate vaccine Prevenar13 (PCV13) and pneumococcal polyvalent vaccine Pneumovax 23 (PPV23) with a 95% vaccination coverage, are recorded after 2 years. The economic benefit of vaccination by reducing the possible number of pneumonias at the end of 2028 will be 968.2 million rubles.Conclusion. The economic feasibility of vaccine prophylaxis of the adult contingent with an increased risk of developing pneumococcal infection has been established. The sequential strategy of PCV13 and PPV23 application provides the most effective localization of pneumococcal infection. The research results should be widely introduced into the long-term plans for vaccination and healthcare practice in the Astrakhan region.

show abstract

Section: Issn 2307-9266 E-issn 2413-2241mentioning

confidence: 99%

“…The current situation already calls for specific vaccination in risk groups. In cases of COPD, vaccination reduces the number of exacerbations, stabilizes the performance of functional tests, it also helps slow down the progression of respiratory failure [9,10]. The relevance of vaccination increases with comorbid pathology.…”

Section: Introductionmentioning

confidence: 99%

Pharmacoeconomic Evaluation of Anti-Pneumococcal Vaccination in Risk Groups for the Prevention of Community-Acquired Pneumonia Among Adults in the Astrakhan Region

Орлова

Дорфман

Орлов

et al. 2021

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

show abstract

Federal Clinical Guidelines on Vaccination of pneumococcal infection in children and adults

Avdeev,

Alyeva,

Baranov

et al. 2023

Profil. med.

View full text Add to dashboard Cite

A Decade of Experience in the use of 13-Valent Conjugated Polysaccharide Pneumococcal Vaccine in Russian Federation

Briko,

Korshunov,

Lobzin

et al. 2023

Epidemiology and Vaccinal Prevention

View full text Add to dashboard Cite

Pneumococcal infection remains a significant global health problem, and vaccination is the main measure for its prevention. To date, the period of use of pneumococcal conjugated polysaccharide vaccines in Russia exceeds 14 years, and 13-valent conjugated polysaccharide pneumococcal vaccine (PCV13) - more than 10 years. During this time, extensive experience has been accumulated in the use of this type of vaccines, and many studies have been carried out to evaluate their effectiveness and safety.The purpose of this review is to summarize the experience of using PCV13 in Russian Federation with an assessment of its epidemiological and clinical effectiveness. A search was made for scientific publications devoted to the study of the epidemiological efficacy, the safety as well as cost-effectiveness of PCV13 use in Russian Federation. The review included original studies published in Russian journals. The results of the studies carried out indicate the efficacy and safety of PCV13 for both adults and children. The effectiveness of immunization of children at risk (premature, suffering from congenital pathology, having chronic diseases and often ill) was demonstrated, the need and safety of the timely start of vaccination (from 2 months of age) of newborns was shown, the possibility of its combination with immunization against other infections within the framework of the national vaccination schedule, the importance of following the recommended vaccination schedule in accordance with the age of the child. The effectiveness of vaccination of adults suffering from chronic diseases has been shown both in terms of preventing the aggravation of the course of the underlying pathology and reducing the risk of pneumonia. Positive experience has been gained in immunizing adults from occupational risk groups - medical workers, conscripts and persons exposed to a harmful production factor and having occupational lung diseases. The conducted studies have shown a high cost-effectiveness of PCV13 vaccination, however, with any changes in price and epidemiological parameters, it is necessary to clarify the economic feasibility of vaccination under the changed conditions. Taking into account the positive experience gained in immunization, it seems appropriate to further maintain a high level of vaccination coverage of the child population, expanding risk groups among the adult population subject to vaccination against pneumococcal infection within the framework of the National Immunization Schedule, taking into account its epidemiological, clinical and economic efficiency.

show abstract

Comparison of quality of life in patients with chronic obstructive pulmonary disease vaccinated with 13-valent conjugate pneumococcal vaccine or 23-valent polysaccharide pneumococcal vaccine

Cited by 3 publications

References 0 publications

Pharmacoeconomic Evaluation of Anti-Pneumococcal Vaccination in Risk Groups for the Prevention of Community-Acquired Pneumonia Among Adults in the Astrakhan Region

Pharmacoeconomic Evaluation of Anti-Pneumococcal Vaccination in Risk Groups for the Prevention of Community-Acquired Pneumonia Among Adults in the Astrakhan Region

Federal Clinical Guidelines on Vaccination of pneumococcal infection in children and adults

A Decade of Experience in the use of 13-Valent Conjugated Polysaccharide Pneumococcal Vaccine in Russian Federation

Contact Info

Product

Resources

About